Richard S Finn, MD
UCLA Department of Medicine, Division of Hematology-Oncology · University of California, Los Angeles
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard S Finn, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:14 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04777851 · Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7Translational Research in Oncology · terminated · Carcinoma, Hepatocellular · study chair
- Ph1NCT03132792 · AFPᶜ³³²T in Advanced HCCAdaptimmune · completed · Hepatocellular Cancer, AFP Expressing Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.